Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

Over the last 30 days, this estimate has changed -1.6%. For the next fiscal year, the consensus earnings estimate of $9.64 indicates a change of +22.4% from what Merck is expected to report a year ...

Merck’s MRK stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals industry. The stock has also underperformed the sector and the S&P 500 ...

sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Merck shares, which were up about 1.4% before the news, slumped and were recently down 1.6%.